EMPA-REG OUTCOME: Analysis in Women with T2DM and CVD

Slideshow

A recent trial found that empagliflozin can reduce the risk of cardiovascular deaths in type 2 diabetes patients; are results similar in men and women?

   

Related Videos
Video 4 - "Innovations in Small Interfering RNA (siRNA) Therapy"
Video 3 - "Ongoing Lp(a) Trials and Clinical Approaches to Treatment"
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Payal Kohli, MD | Credit: Cherry Creek Heart
Matthew Nudy, MD | Credit: Penn State Health
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
Kelley Branch, MD, MS | Credit: University of Washington Medicine
David Berg, MD, MPH | Credit: Brigham and Women's
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Related Content
1 in 12 Lupus Neprhitis Patients Experience Cardiovascular Events

1 in 12 Lupus Neprhitis Patients Experience Cardiovascular Events

May 14th 2024
Article
2024 State of the Air: Record Highs in US Particle Pollution, with Dr. John Balmes

2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD

April 24th 2024
Podcast
Nieca Goldberg, MD | Credit: NYU Langone Health

Nieca Goldberg, MD: Important Women's Heart Health Updates from ACC.24

May 13th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: STEP HFpEF DM and Fair Allocation of Incretin-Based Therapies

April 17th 2024
Podcast
HCPLive Cardiology Month in Review: April 2024

Cardiology Month in Review: April 2024

May 2nd 2024
Article
| Image Credit: National Defense Medical Center

AI-Enabled Electrocardiogram Alert Intervention Reduces All-Cause Mortality

May 1st 2024
Article
© 2024 MJH Life Sciences

All rights reserved.